Literature DB >> 2869776

Fenoldopam: effect on aldosterone secretion.

A G Dupont, P Vanderniepen, A Volckaert, J Smitz, A C Vansteirteghem, R O Six.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 2869776      PMCID： PMC1400917          DOI： 10.1111/j.1365-2125.1986.tb05185.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  5 in total

1.  Dopaminergic modulation of aldosterone secretion in man is unaffected by glucocorticoids and angiotensin blockade.

Authors:  J R Sowers; A S Brickman; D K Sowers; G Berg
Journal:  J Clin Endocrinol Metab       Date:  1981-06       Impact factor: 5.958

2.  Dopaminergic inhibition of metoclopramide-induced aldosterone secretion in man. Dissociation of responses to dopamine and bromocriptine.

Authors:  R M Carey; M O Thorner; E M Ortt
Journal:  J Clin Invest       Date:  1980-07       Impact factor: 14.808

3.  The effect of oral fenoldopam (SKF 82526-J), a peripheral dopamine receptor agonist, on blood pressure and renal function in normal man.

Authors:  J N Harvey; D P Worth; J Brown; M R Lee
Journal:  Br J Clin Pharmacol       Date:  1985-01       Impact factor: 4.335

4.  Tonic dopaminergic suppression of plasma aldosterone.

Authors:  R H Noth; R W McCallum; C Contino; J Havelick
Journal:  J Clin Endocrinol Metab       Date:  1980-07       Impact factor: 5.958

Review 5.  Metoclopramide. An updated review of its pharmacological properties and clinical use.

Authors:  R A Harrington; C W Hamilton; R N Brogden; J A Linkewich; J A Romankiewicz; R C Heel
Journal:  Drugs       Date:  1983-05       Impact factor: 9.546
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.